ArticleRespiratory medicine case reports2025
Mesalazine-associated lung fibrosis: case report and literature review.
Article in Respiratory medicine case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Even though uncommon, drug-induced interstitial lung disease (DIILD) represents a serious adverse drug reaction. We report a case of a patient with a history of ulcerative colitis who was receiving mesalazine. Presentation: The patient developed dyspnea, hypoxemia, and respiratory failure accompanied by resting oxygen desaturation. Initial CT imaging revealed bilateral perihilar ground-glass opacities along with focal areas of consolidation. Inflammatory markers were elevated, but procalcitonin levels remained persistently low; sputum cultures and multiplex PCR ruled against an infectious origin. Mesalazine was discontinued, and the patient's respiratory status improved dramatically. Follow-up CT revealed interval resolution of the pulmonary lesions, and a diagnosis of DIILD was clinically established. Conclusion: This case emphasizes the importance of balancing clinical suspicion between steroid-related infectious risk and an uncommon drug reaction. We also identified similar Mesalazine-associated DIILD cases in the literature to demonstrate similar radiologic patterns, onset time, and outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.